# A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject

> **NCT01917357** · PHASE3 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 400 (actual)

## Conditions studied

- Diphtheria
- Pertussis
- Tetanus
- Hepatitis B
- Haemophilus Infections

## Interventions

- **BIOLOGICAL:** Quinvaxem in Uniject
- **BIOLOGICAL:** Quinvaxem in single dose vials

## Key facts

- **NCT ID:** NCT01917357
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2014-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01917357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01917357, "A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01917357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*